The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide ... risks. I am a physician ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions. This association is being called “Ozempic blindness.” Experts are not entirely clear why ...

Sold under brand names including Wegovy and Ozempic, semaglutide works by mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), hence the technical term for it is a GLP-1 receptor agonist.

Semaglutide, in its Ozempic incarnation ... I’ve told a few people about this, and the disapproval feels thick. Like having addiction issues, weight is often viewed through a lens of blame.

no shortcuts, no surgery, no Ozempic. That only does weight loss, not this. Right? Within four to six months, I am going to get a rock solid six-pack with blocks. That has to be done the hard way.

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.